Latest stock market news, company updates, and price movements. Stay updated with market trends, earnings insights, and investment analysis.
AceVector plans a Rs 50 crore, three-year debenture at 14.50% after reporting Rs 21.797 crore of operating cash outflow in fiscal 2026.
Snapdeal’s FY26 revenue rose 17.5% to Rs 293.675 crore, but adjusted EBITDA loss widened to Rs 50.251 crore despite a narrower margin.
Acevector’s marketplace defence is under test in drug, cooker, toy and plastic proceedings, while it discloses 72 pending consumer complaints.
AceVector keeps Unicommerce consolidated through board-appointment and management-control rights despite 26.13% ownership; SaaS supplied Rs 204.338 crore, or 40.04%, of Financial Year 2026 revenue.
Snapdeal cut marketplace monetisation by 13.06 percentage points to 26.87% of NMV in Financial Year 2026 as its zero-commission model sought lower prices.
Radhagobind Commercial disclosed the outcome of its 10th committee of creditors meeting as the company continues its IBC-led CIRP, with shares at Rs 1.96.
Sterlite Tech is in focus after a CLSA target hike, US certification for AI data centre fibre assemblies, and capex-led capacity plans that have driven a sharp 2026 rally.
SEBI’s latest study shows nearly nine in ten individual F&O traders lose money, driven by option buying, near-expiry bets, high leverage, costs, and behavioural errors.
Online discussion around Budget 2026 focuses on optional joint taxation for married couples, with debates on fairness, revenue impact, consumption support, and safeguards in final drafting.
SEBI’s tighter algo framework and proposed derivatives tax hikes are reshaping high-frequency trading economics, even as top firms report rising India profits and retail losses deepen.
Natco Pharma has received in-principle approvals from BSE and NSE for listing its proposed rights issue shares, a procedural step after the board cleared a ₹1,300 crore plan.
September has seen FPIs turn sellers again in Indian equities, with over Rs 23,000 crore withdrawn amid higher crude, firm US yields, geopolitical risk and rupee weakness.
Arvaya Healthcare’s September 21, 2026 AGM will consider FY27 related-party transactions worth ₹390 crore, MD reappointment, and an IP acquisition proposal funded via rights issue proceeds.
Mphasis has set a July 23, 2026 board meeting for audited June-quarter results and scheduled an 8:30 am investor call and webcast on July 24, 2026.
Gujarat Themis Biosyn has issued an addendum for its September 30, 2026 AGM, seeking shareholder approval to widen the definition of “Financial Institution” and enable board observers for lenders.
Refex Industries completed postal ballot notice dispatch on March 31, 2026, and later held NCLT-directed meetings on August 5, 2026 for a composite amalgamation scheme.